文献速递血栓与止血

艾美赛珠单抗在重型A型血友病患者中止血活性的多中心评估

Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A.
PubMed 文献 · J Thromb Haemost · 2024-04-06

本研究在多中心评估改良凝血酶生成试验(TGA)能否反映艾美赛珠单抗的止血活性,并比较TGA与三种艾美赛珠单抗浓度检测方法的相关性。结果显示,TGA的内源性凝血酶潜能与患者临床反应相关,纤维蛋白凝块超微结构与ETP结果一致,艾美赛珠单抗止血活性相当于20至30 IU/dL的FVIII;ETP与LC-MS及改良一步法FVIII检测无相关性,但LC-MS方法与TGA达峰时间呈统计学显著相关。

要点

  • 改良TGA的ETP与艾美赛珠单抗临床反应相关,突破性出血患者凝血酶生成能力较低。
  • 纤维蛋白凝块超微结构显示艾美赛珠单抗止血活性相当于20至30 IU/dL的FVIII。
  • ETP与LC-MS及改良一步法FVIII检测无相关性,LC-MS与TGA达峰时间呈统计学显著相关。

核心结论

  • 使用改良TGA,本研究表明在艾美赛珠单抗治疗期间发生突破性出血的患者,其凝血酶生成能力低于临床反应良好的患者。

研究设计与样本

  • 多中心评估研究,采用改良TGA(极低浓度组织因子与活化FXI联合触发)检测血小板贫乏血浆,并用改良一步法FVIII检测及两种基于液相色谱-质谱联用(LC-MS)的方法定量艾美赛珠单抗。

主要发现

  • 使用组织因子/活化FXI触发的TGA和血小板贫乏血浆,观察到凝血酶生成曲线下面积(内源性凝血酶潜能[ETP])与患者对艾美赛珠单抗的临床反应之间存在关系。
  • 纤维蛋白凝块超微结构与ETP结果一致,显示艾美赛珠单抗的止血活性相当于20至30 IU/dL的FVIII。
  • 药代动力学/药效学分析显示,ETP与LC-MS及改良一步法FVIII检测均无相关性,但LC-MS方法与TGA的达峰时间结果之间呈统计学显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emicizumab has been approved for the prophylaxis of patients with hemophilia A with or without inhibitors. However, spontaneous and trauma-induced breakthrough bleeds have been reported in patients on emicizumab prophylaxis, and no laboratory assay has been validated to evaluate the hemostatic activity of emicizumab. OBJECTIVES: The thrombin generation assay (TGA) could be a surrogate marker of the hemostatic efficacy of emicizumab. The correlation between TGA and the methods used to measure emicizumab blood concentration was evaluated in this study. METHODS: TGA was modified by the use of a trigger reagent combining a very low concentration of tissue factor and activated factor (F)XI. Emicizumab quantification was performed by 3 methods: the modified 1-step FVIII assay and 2 methods based on liquid chromatography and mass spectrometry (LC-MS). RESULTS: Using tissue factor/activated FXI-triggered TGA and platelet-poor plasma, a relationship was observed between the area under the thrombin generation curve (endogenous thrombin potential [ETP]) and the clinical response of patients to emicizumab. The ultrastructure of fibrin clots was consistent with ETP results and showed that emicizumab had a hemostatic activity equivalent to 20 to 30 IU/dL of FVIII. Finally, pharmacokinetic/pharmacodynamic analyses showed no correlation between ETP and LC-MS nor with modified 1-stage FVIII assay, but a statistically significant correlation between the LC-MS methods and the time-to-peak results of the TGA. CONCLUSION: Using a modified TGA, this study showed that patients who experienced breakthrough bleeds while on emicizumab had a lower thrombin-generating capacity compared with others with good clinical response to emicizumab.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Josset L, Leuci A, Janbain M, et al. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A. J Thromb Haemost. 2024. PMID: 38583717. doi:10.1016/j.jtha.2024.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。